The correlation between plasma levels of oxytocin and betatrophin in non-diabetic and diabetic metabolic syndrome patients: A cross sectional study from Jordan

Al-Rawashdeh, Amani; Kasabri, Violet; Bulatova, Nailya; Akour, Amal; Zayed, Ayman A.; Momani, Munther; Khawaja, Nahla; Bustanji, Haider; Hyasat, Dana

doi:10.1016/j.dsx.2016.08.008

Cited by 23 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, a comprehensive meta-analysis by Li et al suggested that circulating betatrophin levels in T2D nonobese patients are higher than those in the nondiabetic control group [9]. Moreover, recent studies showed that plasma concentrations of metabolic markers, for example, betatrophin, as well as hepatocyte growth factor and nesfatin, are elevated in drugnaïve prediabetic and T2D patients in comparison to normoglycemic subjects [18,19]. It has also been observed that serum betatrophin concentration positively correlated with HbA1c and fasting plasma glucose in the group of patients with diabetes, prediabetic state, and metabolic syndrome [19] and with fasting plasma glucose and HOMA-IR in T2D and nondiabetic subjects [20].…”

Section: Introductionmentioning

confidence: 99%

Serum concentrations of betatrophin and its association with indirect indices of insulin resistance and beta cell function in women with polycystic ovary syndrome

Adamska¹,

Łebkowska²,

Jacewicz³

et al. 2017

EJEA

View full text Add to dashboard Cite

Introduction. Data underline the role of betatrophin in glucose homeostasis. Polycystic ovary syndrome (PCOS) is characterized by insulin resistance (IR). The aim of our study was to investigate the relationship of serum betatrophin concentrations with indirect indices of IR and insulin secretion in women with PCOS, compared to the control group. Methods. The study group comprised 43 women with PCOS and 16 controls. IR was assessed by HOMA-IR and Matsuda index. Insulin secretion was evaluated with HOMA-B. An oral glucose tolerance test (OGTT) with estimation of serum betatrophin concentrations was performed. Results. Glucose load resulted in an increase in serum betatrophin concentrations in the control group (p = 0 02). Serum betatrophin concentrations at 120 min of OGTT were lower in women with PCOS than in the control group (p = 0 02). We observed positive correlations between baseline serum betatrophin concentrations and HOMA-IR (r = 0 39, p = 0 008), negative correlations with Matsuda index (r = −0 31, p = 0 004), and a positive relationship with HOMA-B (r = 0 38, p = 0 01) in women with PCOS. Multiple regression analysis revealed that HOMA-B (β = 0 47, p = 0 001) was an independent factor connected to serum betatrophin levels in PCOS. Conclusions. Serum concentrations of betatrophin are connected with insulin resistance and beta cell function and did not change after glucose load in women with PCOS.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum concentrations of betatrophin and its association with indirect indices of insulin resistance and beta cell function in women with polycystic ovary syndrome

Adamska¹,

Łebkowska²,

Jacewicz³

et al. 2017

EJEA

View full text Add to dashboard Cite

show abstract

“…The apparent discrepancy in the results also suggests that abnormal glycaemia may be a modifying factor in the oxytocin–obesity relationship. The fasting oxytocin concentrations of subjects with metabolic syndrome who also had drug‐naive prediabetes or diabetes were approximately half that of control subjects with metabolic syndrome but had normal glycaemia and HbA1c . In African–American men with overweight and obesity, subjects in the highest tertile for fasting urinary oxytocin – a proxy for peripheral oxytocin levels – had lower weight, HbA1c, oral glucose tolerance test area‐under‐the‐curve insulin and C‐peptide, and liver function enzymes compared with subjects in the lowest tertile.…”

Section: Alterations In the Oxytocin System In Obesity And Diabetesmentioning

confidence: 98%

Oxytocin in metabolic homeostasis: implications for obesity and diabetes management

2018

View full text Add to dashboard Cite

Summary Oxytocin was once understood solely as a neuropeptide with a central role in social bonding, reproduction, parturition, lactation and appetite regulation. Recent evidence indicates that oxytocin enhances glucose uptake and lipid utilization in adipose tissue and skeletal muscle, suggesting that dysfunction of the oxytocin system could underlie the pathogenesis of insulin resistance and dyslipidaemia. Murine studies revealed that deficiencies in oxytocin signalling and oxytocin receptor expression lead to obesity despite normal food intake, motor activity and increased leptin levels. In addition, plasma oxytocin concentration is notably lower in obese individuals with diabetes, which may suggest an involvement of the oxytocin system in the pathogenesis of cardiometabolic disease. More recently, small scale studies demonstrated that intranasal administration of oxytocin was associated with significant weight loss as well as improvements in insulin sensitivity and pancreatic β‐cell responsivity in human subjects. The multi‐pronged effects of oxytocin signalling on improving peripheral insulin sensitivity, pancreatic function and lipid homeostasis strongly suggest a role for this system as a therapeutic target in obesity and diabetes management. The complexity of obesity aetiology and the pathogenesis of obesity‐related metabolic complications underscore the need for a systems approach to better understand the role of oxytocin in metabolic function.

show abstract

“…In humans, studies have shown that peripheral OT levels are elevated in obesity and the metabolic syndrome, and correlate with BMI and fat mass . Conversely, OT concentrations may be lowered in the presence of overt diabetes . Acutely, intranasal OT administration reduces caloric intake with a preferential reduction in fat consumption; as in animals, these effects are more pronounced in obesity .…”

Section: Physiological Effectsmentioning

confidence: 99%

“…21,22 Conversely, OT concentrations may be lowered in the presence of overt diabetes. [23][24][25] Acutely, intranasal OT administration reduces caloric intake 26,27 with a preferential reduction in fat consumption 26 ; as in animals, these effects are more pronounced in obesity. 27 These actions may be mediated at least in part by modification of hedonic as well as homoeostatic pathways.…”

Section: Phys I Olog I C Al Effec Tsmentioning

confidence: 99%

Oxytocin therapy in hypopituitarism: Challenges and opportunities

Bhargava

Daughters

Rees

2018

Clinical Endocrinology

View full text Add to dashboard Cite

Summary Patients with hypopituitarism display impaired quality of life and excess morbidity and mortality, despite apparently optimal pituitary hormone replacement. Oxytocin is a neuropeptide synthesized in the anterior hypothalamus which plays an important role in controlling social and emotional behaviour, body weight and metabolism. Recent studies have suggested that a deficiency of oxytocin may be evident in patients with hypopituitarism and craniopharyngioma, and that this may be associated with deficits in cognitive empathy. Preliminary data hint at potential benefits of oxytocin therapy in improving these deficits and the accompanying metabolic disturbances that are common in these conditions. However, several challenges remain, including an incomplete understanding of the regulation and mechanisms of action of oxytocin, difficulties in accurately measuring oxytocin levels and in establishing a diagnosis of oxytocin deficiency, and a need to determine both the optimal mode of administration for oxytocin therapy and an acceptable safety profile with long‐term use. This review considers the data linking oxytocin to the neuropsychological and metabolic disturbances evident in patients with craniopharyngioma and hypopituitarism, and describes the challenges that need to be overcome before replacement therapy can be considered as a therapeutic option in clinical practice.

show abstract

The correlation between plasma levels of oxytocin and betatrophin in non-diabetic and diabetic metabolic syndrome patients: A cross sectional study from Jordan

Cited by 23 publications

References 35 publications

Serum concentrations of betatrophin and its association with indirect indices of insulin resistance and beta cell function in women with polycystic ovary syndrome

Serum concentrations of betatrophin and its association with indirect indices of insulin resistance and beta cell function in women with polycystic ovary syndrome

Oxytocin in metabolic homeostasis: implications for obesity and diabetes management

Oxytocin therapy in hypopituitarism: Challenges and opportunities

Contact Info

Product

Resources

About